Callio Therapeutics has raised $187m in a Series A financing round to achieve clinical proof-of-concept for its human epidermal growth factor receptor 2-targeted dual-payload antibody-drug conjugate ...
Callio Therapeutics, a biotherapeutics company advancing dual-payload antibody-drug conjugates (ADCs) with a targeted, multi-mechanism approach to cancer treatment, today announced that it will ...
Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience Financing ...
Biotech-focused investment firm Frazier Life Sciences has launched Callio Therapeutics, a cancer treatment startup with headquarters in Seattle and Singapore. Frazier led a $187 million Series A round ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company is focused on cancer ...
Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload antibody-drug conjugate that’s ready for the clinic. The ADC, and Callio’s ...
Callio Therapeutics is developing novel dual-payload antibody-drug conjugates (ADCs) designed to address resistance to existing cancer therapies, using proprietary linker and ADC platform technologies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results